1. Home
  2. PGY vs RAPP Comparison

PGY vs RAPP Comparison

Compare PGY & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pagaya Technologies Ltd.

PGY

Pagaya Technologies Ltd.

HOLD

Current Price

$12.41

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$27.81

Market Cap

1.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGY
RAPP
Founded
2016
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
PGY
RAPP
Price
$12.41
$27.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
6
Target Price
$34.50
$47.00
AVG Volume (30 Days)
5.5M
316.8K
Earning Date
02-09-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.93
N/A
Revenue
$1,301,360,000.00
N/A
Revenue This Year
$18.57
N/A
Revenue Next Year
$14.58
N/A
P/E Ratio
$13.37
N/A
Revenue Growth
26.07
N/A
52 Week Low
$8.50
$6.43
52 Week High
$44.99
$42.27

Technical Indicators

Market Signals
Indicator
PGY
RAPP
Relative Strength Index (RSI) 24.69 55.76
Support Level $12.05 $26.57
Resistance Level $15.51 $28.99
Average True Range (ATR) 1.34 1.80
MACD -0.72 0.25
Stochastic Oscillator 4.03 92.06

Price Performance

Historical Comparison
PGY
RAPP

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Share on Social Networks: